clinical trial · NCT06561152
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaTagraxofuspCladribine (CLAD)Cytarabine
brief summary
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
started
Feb 10, 2025
primary completion
Oct 1, 2027
completion
Oct 1, 2028
last updated
Apr 14, 2026
official title
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol